Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder

Mithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2 clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resurgence in the studies of this generic antibiotic as a human medicine, we have examined the binding prope...

Full description

Bibliographic Details
Main Authors: Amrita Banerjee, Sulagna Sanyal, Kirti K. Kulkarni, Kuladip Jana, Siddhartha Roy, Chandrima Das, Dipak Dasgupta
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:FEBS Open Bio
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211546314000965
id doaj-012403ddb30946f581669a31e8bb453a
record_format Article
spelling doaj-012403ddb30946f581669a31e8bb453a2020-11-25T02:26:26ZengWileyFEBS Open Bio2211-54632014-01-014C98799510.1016/j.fob.2014.10.007Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binderAmrita Banerjee0Sulagna Sanyal1Kirti K. Kulkarni2Kuladip Jana3Siddhartha Roy4Chandrima Das5Dipak Dasgupta6Biophysics & Structural Genomics Division, Saha Institute of Nuclear Physics, Block-AF, Sector-1, Bidhan Nagar, Kolkata 700064, West Bengal, IndiaBiophysics & Structural Genomics Division, Saha Institute of Nuclear Physics, Block-AF, Sector-1, Bidhan Nagar, Kolkata 700064, West Bengal, IndiaBionivid Technology Pvt Ltd, Kasturi Nagar, Bangalore 560043, IndiaDivision of Molecular Medicine, Centre for Translational Animal Research, Bose Institute, P-1/12 C.I.T. Scheme VIIM, Kolkata 700054, West Bengal, IndiaStructural Biology and Bioinformatics, Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Kolkata 700032, West Bengal, IndiaBiophysics & Structural Genomics Division, Saha Institute of Nuclear Physics, Block-AF, Sector-1, Bidhan Nagar, Kolkata 700064, West Bengal, IndiaBiophysics & Structural Genomics Division, Saha Institute of Nuclear Physics, Block-AF, Sector-1, Bidhan Nagar, Kolkata 700064, West Bengal, IndiaMithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2 clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resurgence in the studies of this generic antibiotic as a human medicine, we have examined the binding properties of MTR with the integral component of chromatin – histone proteins – as a part of our broad objective to classify DNA-binding molecules in terms of their ability to bind chromosomal DNA alone (single binding mode) or both histones and chromosomal DNA (dual binding mode). The present report shows that besides DNA, MTR also binds to core histones present in chromatin and thus possesses the property of dual binding in the chromatin context. In contrast to the MTR–DNA interaction, association of MTR with histones does not require obligatory presence of bivalent metal ion like Mg2+. As a consequence of its ability to interact with core histones, MTR inhibits histone H3 acetylation at lysine 18, an important signature of active chromatin, in vitro and ex vivo. Reanalysis of microarray data of Ewing sarcoma cell lines shows that upon MTR treatment there is a significant down regulation of genes, possibly implicating a repression of H3K18Ac-enriched genes apart from DNA-binding transcription factors. Association of MTR with core histones and its ability to alter post-translational modification of histone H3 clearly indicates an additional mode of action of this anticancer drug that could be implicated in novel therapeutic strategies.http://www.sciencedirect.com/science/article/pii/S2211546314000965MithramycinCore histonesDual binding modeEpigenetic modulatorH3K18 acetylation
collection DOAJ
language English
format Article
sources DOAJ
author Amrita Banerjee
Sulagna Sanyal
Kirti K. Kulkarni
Kuladip Jana
Siddhartha Roy
Chandrima Das
Dipak Dasgupta
spellingShingle Amrita Banerjee
Sulagna Sanyal
Kirti K. Kulkarni
Kuladip Jana
Siddhartha Roy
Chandrima Das
Dipak Dasgupta
Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
FEBS Open Bio
Mithramycin
Core histones
Dual binding mode
Epigenetic modulator
H3K18 acetylation
author_facet Amrita Banerjee
Sulagna Sanyal
Kirti K. Kulkarni
Kuladip Jana
Siddhartha Roy
Chandrima Das
Dipak Dasgupta
author_sort Amrita Banerjee
title Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
title_short Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
title_full Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
title_fullStr Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
title_full_unstemmed Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
title_sort anticancer drug mithramycin interacts with core histones: an additional mode of action of the dna groove binder
publisher Wiley
series FEBS Open Bio
issn 2211-5463
publishDate 2014-01-01
description Mithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2 clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resurgence in the studies of this generic antibiotic as a human medicine, we have examined the binding properties of MTR with the integral component of chromatin – histone proteins – as a part of our broad objective to classify DNA-binding molecules in terms of their ability to bind chromosomal DNA alone (single binding mode) or both histones and chromosomal DNA (dual binding mode). The present report shows that besides DNA, MTR also binds to core histones present in chromatin and thus possesses the property of dual binding in the chromatin context. In contrast to the MTR–DNA interaction, association of MTR with histones does not require obligatory presence of bivalent metal ion like Mg2+. As a consequence of its ability to interact with core histones, MTR inhibits histone H3 acetylation at lysine 18, an important signature of active chromatin, in vitro and ex vivo. Reanalysis of microarray data of Ewing sarcoma cell lines shows that upon MTR treatment there is a significant down regulation of genes, possibly implicating a repression of H3K18Ac-enriched genes apart from DNA-binding transcription factors. Association of MTR with core histones and its ability to alter post-translational modification of histone H3 clearly indicates an additional mode of action of this anticancer drug that could be implicated in novel therapeutic strategies.
topic Mithramycin
Core histones
Dual binding mode
Epigenetic modulator
H3K18 acetylation
url http://www.sciencedirect.com/science/article/pii/S2211546314000965
work_keys_str_mv AT amritabanerjee anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT sulagnasanyal anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT kirtikkulkarni anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT kuladipjana anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT siddhartharoy anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT chandrimadas anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
AT dipakdasgupta anticancerdrugmithramycininteractswithcorehistonesanadditionalmodeofactionofthednagroovebinder
_version_ 1724847109711069184